[1] Liu J, Grohganz H, Löbmann K, Rades T, Hempel NJ. Co-Amorphous Drug Formulations in Numbers: Recent Advances in Co-Amorphous Drug Formulations with Focus on Co-Formability, Molar Ratio, Preparation Methods, Physical Stability, In Vitro and In Vivo Performance, and New Formulation Strategies. Pharmaceutics. 2021 Mar 15;13(3):389. doi: 10.3390/pharmaceutics13030389. PMID: 33804159; PMCID: PMC7999207.
[2] Bahetibieke, S.; Moinuddin, S.M.; Baiyisaiti, A.; Liu, X.; Zhang, J.; Liu, G.; Shi, Q.; Peng, A.; Tao, J.; Di, C.; Cai, T.; Qi, R. Co-Amorphous Formation of Simvastatin-Ezetimibe: Enhanced Physical Stability, Bioavailability and Cholesterol-Lowering Effects in LDLr−/−Mice. Pharmaceutics 2022, 14, 1258. https://doi.org/10.3390/pharmaceutics14061258
[3] 方晓萍,胡义,卢山,曹艳.共无定形药物的研究进展[J].中国医药工业杂志,2022,53(07):953-961.DOI:10.16522/j.cnki.cjph.2022.07.004.
[4] Swapnil Jayant Dengale, Holger Grohganz, Thomas Rades, Korbinian Löbmann.Recent advances in co-amorphous drug formulations[J].Advanced drug delivery reviews, 2016. https://doi.org/10.1016/j.addr.2015.12.009.